Skip to main content
Journal cover image

Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

Publication ,  Journal Article
Long, GV; Milhem, M; Amin, A; Hoimes, CJ; Medina, T; Conry, RM; Lao, C; Daniels, G; Reddy, S; Mehmi, I; Andtbacka, RHI; Barve, M; Shaheen, M ...
Published in: Annals of oncology : official journal of the European Society for Medical Oncology
October 1, 2018

Duke Scholars

Published In

Annals of oncology : official journal of the European Society for Medical Oncology

DOI

EISSN

1569-8041

Publication Date

October 1, 2018

Volume

29

Start / End Page

viii736

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Long, G. V., Milhem, M., Amin, A., Hoimes, C. J., Medina, T., Conry, R. M., … Ribas, A. (2018). Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29, viii736. https://doi.org/10.1093/annonc/mdy424.055
Long, G. V., M. Milhem, A. Amin, C. J. Hoimes, T. Medina, R. M. Conry, C. Lao, et al. “Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii736. https://doi.org/10.1093/annonc/mdy424.055.
Long GV, Milhem M, Amin A, Hoimes CJ, Medina T, Conry RM, et al. Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii736.
Long, G. V., et al. “Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, Oct. 2018, p. viii736. Scopus, doi:10.1093/annonc/mdy424.055.
Long GV, Milhem M, Amin A, Hoimes CJ, Medina T, Conry RM, Lao C, Daniels G, Reddy S, Mehmi I, Andtbacka RHI, Barve M, Shaheen M, Tueting T, Chisamore M, Xing B, Candia A, Gamelin E, Janssen R, Ribas A. Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii736.
Journal cover image

Published In

Annals of oncology : official journal of the European Society for Medical Oncology

DOI

EISSN

1569-8041

Publication Date

October 1, 2018

Volume

29

Start / End Page

viii736

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis